BLA
HBIO icon

Balter Liquid Alternatives’s Harvard Bioscience HBIO Stock Holding History

Balter Liquid Alternatives’s Portfolio HBIO Stock Details HBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,919
Closed -$49K – 146
2017
Q2 		$49K Buy
+1,919
New +$47.5K 0.06% 129

Other funds holding HBIO

FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GPC
Glacier Peak Capital Bellevue, Washington $96.2M AUM 0.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
FP
Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

Balter Liquid Alternatives's HBIO Position: Q3 2017 in Review

Balter Liquid Alternatives sold out of Harvard Bioscience (HBIO) in Q3 2017, closing a stake of 1,919 shares — an estimated $49K sold.

Balter Liquid Alternatives first reported a position in HBIO in Q2 2017 and held it in 1 quarter. The position peaked at $49K in Q2 2017. 53 funds tracked by Wall St. Rank hold HBIO as of Q3 2017.

  • Balter Liquid Alternatives reported no remaining Harvard Bioscience position as of Q3 2017 after selling out during the quarter.
  • Balter Liquid Alternatives sold 1,919 Harvard Bioscience shares in Q3 2017, an estimated $49K.
  • Balter Liquid Alternatives first reported a position in Harvard Bioscience in Q2 2017 and held it in 1 quarter.
  • Balter Liquid Alternatives's Harvard Bioscience position peaked at $49K in Q2 2017.
  • 53 funds tracked by Wall St. Rank held Harvard Bioscience as of Q3 2017.

Based on Balter Liquid Alternatives's 13F filing for Q3 2017, filed 16 Oct 2017.